StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report released on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm dropped their target price on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd.
Get Our Latest Research Report on Aptevo Therapeutics
Aptevo Therapeutics Stock Performance
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. Sell-side analysts expect that Aptevo Therapeutics will post -2.97 EPS for the current fiscal year.
Institutional Trading of Aptevo Therapeutics
A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Articles
- Five stocks we like better than Aptevo Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 REITs to Buy and Hold for the Long Term
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Best Stocks Under $10.00
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.